{"analyses":[{"groupDescription":"Abnormal at Screening","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3168","statisticalComment":"If any cell count is \\<5, p-value was based on Fisher's exact test","statisticalMethod":"1-sided p-value based on Chi-Square test"},{"groupDescription":"Abnormal after remission","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2160","statisticalComment":"If any cell count is \\<5, p-value was based on Fisher's exact test","statisticalMethod":"1-sided p-value based on Chi-Square test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"12.7","value":"3.7"},{"groupId":"OG001","lowerLimit":"5.2","upperLimit":"40.3","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Karyotyping was required locally, at screening and at least once during the study in participants who had abnormal cytogenetics at baseline and who achieved CR/CRi. Data presented below are for participants who achieved CR/CRi per EAC and had abnormal karyotype at screening.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with inotuzumab ozogamicin at a starting dose of 1.8 mg/m\\^2 (according to body surface area) per cycle with a divided-dose regimen using 3 weekly administrations. Participants received 0.8 mg/m\\^2/cycle on Week 1 (Day 1), followed by 0.5 mg/m\\^2 on Week 2 (Day 8) and Week 3 (Day 15) of a 21-day cycle, and administered as an intravenous infusion over 60 minutes. For participants who achieved a CR or CRi, or to allow recovery from toxicity, the length of Cycle 1 could be extended up to 28 days (ie, 1 week treatment-free interval starting on Day 21). For participants who achieved CR or CRi, the inotuzumab ozogamicin dose administered on Week 1 was reduced to 0.5 mg/m\\^2 (for a total cycle dose of 1.5 mg/m\\^2/cycle) for Cycles 2 through 6 (maximum number of cycles permitted). For Cycles 2 through 6, the cycle length was 28 days for all participants (regardless of remission status).","id":"OG000","title":"Inotuzumab Ozogamicin"},{"description":"Participants received fludarabine, cytarabine, granulocyte-colony stimulating factor (FLAG), mitoxantrone + cytarabine (MXN/Ara-C), or high-dose cytarabine (HIDAC), according to the Investigator's choice.","id":"OG001","title":"Defined Investigator's Choice of Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Participants in the ITT218 population who had abnormal cytogenetics at baseline and who achieved CR/CRi","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 weeks (EoT) from last dose of study drug","title":"Cytogenetic Status (Based on Local Laboratory Analysis) of Participants With CR/CRi (Per EAC Assessment)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}